StemImmune HematoGen™ Complete Differentiation System
StemImmune HematoGen™ Complete Differentiation System
Defined, stage-specific cytokine system for differentiation of human iPSC/ESC into hemogenic endothelium and hematopoietic progenitor cells
Product Overview
HematoGen™ Complete Differentiation System is a modular, development-inspired cytokine platform designed to support the differentiation of human iPSC or ESC into mesoderm, hemogenic endothelium, endothelial-to-hematopoietic transition (EHT), and HSPC-like populations.
Instead of using a single undefined cocktail, HematoGen™ organizes the workflow into biologically relevant stages to help improve reproducibility, simplify optimization, and support downstream hematopoietic research applications.
Key Benefits
Stage-Specific Design
Supports key developmental transitions from pluripotent stem cells to hematopoietic progenitor-like populations using defined stage modules.
Improved Workflow Clarity
Day-by-day organization makes protocol implementation easier and helps researchers associate each stage with the correct kit.
Modular and Flexible
Individual stages can be used separately or as a full workflow, allowing adaptation to different cell lines and downstream applications.
Applications
Stem Cell Differentiation
Support generation of mesoderm, hemogenic endothelium, EHT intermediates, and hematopoietic progenitor populations.
Developmental Biology
Model key steps in human hematopoietic development in a structured, stage-specific manner.
Disease Modeling
Generate hematopoietic intermediates for functional studies, screening workflows, and gene-editing research.
Downstream Lineage Studies
Use generated progenitors as inputs for erythroid, myeloid, lymphoid, or NK-cell directed workflows.
Product Specifications
| Product Name | StemImmune HematoGen™ Complete Differentiation System |
|---|---|
| Application | Human iPSC/ESC differentiation into hemogenic endothelium and hematopoietic progenitor populations |
| Format | Stage-specific modular cytokine system |
| Species | Human |
| Recommended Use | Research use only |
| Workflow | 4-step differentiation system with dedicated stage kits |
4-Step Differentiation Workflow
The HematoGen™ workflow begins with healthy human iPSC/ESC cultures and progresses through four defined stages using dedicated kit modules.
Kit Components
| Stage | Kit | Day Range | Representative Factors | Primary Purpose |
|---|---|---|---|---|
| Stage 1 | HG-MESO | Day 0–2 | BMP-4 , Activin A , FGF2, CHIR99021 | Supports mesoderm induction from human iPSC/ESC |
| Stage 2 | HG-HE | Day 2–6 | VEGF-A, FGF2, SCF, SB431542 | Promotes hemogenic endothelium formation |
| Stage 3 | HG-EHT | Day 5–10 | SCF, TPO, FLT3L, IL-3, IL-6, UM171*, SR1* | Supports endothelial-to-hematopoietic transition and progenitor emergence |
| Stage 4 | HG-HSPC | Day 8+ | SCF, TPO, FLT3L, UM171*, SR1* | Supports HSPC-like expansion |
Ordering Information
| Catalog No. | Product Name | Format |
|---|---|---|
| HG-COMPLETE-10 | HematoGen™ Complete Differentiation System | 10 reactions |
| HG-MESO-10 | HG-MESO Mesoderm Induction Kit | 10 reactions |
| HG-HE-10 | HG-HE Hemogenic Endothelium Kit | 10 reactions |
| HG-EHT-10 | HG-EHT Endothelial-to-Hematopoietic Transition Kit | 10 reactions |
| HG-HSPC-10 | HG-HSPC Expansion Kit | 10 reactions |
Suggested Protocol
| Day | Stage | Kit | Suggested Action |
|---|---|---|---|
| Day 0 | Cell Preparation | — | Plate healthy human iPSC/ESC under optimized pluripotent stem cell culture conditions. |
| Day 0–2 | Mesoderm Induction | HG-MESO | Apply mesoderm induction medium and maintain cells under recommended differentiation conditions. |
| Day 2–6 | Hemogenic Endothelium | HG-HE | Switch to hemogenic endothelium induction medium to support endothelial / HE intermediate formation. |
| Day 5–10 | Endothelial-to-Hematopoietic Transition | HG-EHT | Apply EHT-stage factors to support emergence of hematopoietic progenitor-like populations. |
| Day 8+ | HSPC Expansion | HG-HSPC | Expand HSPC-like cells for downstream analysis and lineage-specific workflows. |
Recommended Readouts
Stage 1
Observe early mesoderm transition and confirm expected morphology changes.
Stage 2
Evaluate endothelial / hemogenic endothelial intermediate formation.
Stage 3
Monitor appearance of hematopoietic progenitor-associated markers and suspension cells if applicable.
Stage 4
Assess expansion and maintenance of HSPC-like populations for downstream research use.
Suggested QC Markers
| Stage | Suggested Markers | Purpose |
|---|---|---|
| Mesoderm | Brachyury (T), KDR / CD309 | Confirm early mesoderm induction |
| Hemogenic Endothelium | CD34, CD144 (VE-cadherin), CD309 (KDR), SOX17 | Evaluate endothelial / hemogenic endothelial intermediate formation |
| EHT / Hematopoietic Emergence | CD43, CD45, CD34, RUNX1C | Monitor endothelial-to-hematopoietic transition |
| HSPC-Like Population | CD34, CD45, CD90, CD49f | Characterize primitive hematopoietic phenotypes |
Frequently Asked Questions
Does this system generate true transplantable HSCs?
HematoGen™ is positioned to support generation of hemogenic endothelium, hematopoietic progenitor, and HSPC-like populations from human pluripotent stem cells for research applications. It is not marketed as a validated clinical or transplant-grade HSC system.
Can I use one stage only?
Yes. The HematoGen™ platform is modular, so individual stages such as HG-HE, HG-EHT, or HG-HSPC can be used separately depending on your workflow.
Which cell types is this designed for?
This system is intended for use with human iPSC and human ESC differentiation workflows.
What can the generated cells be used for?
Generated progenitor-like populations can support downstream hematopoietic research, including erythroid, myeloid, lymphoid, developmental biology, and disease-modeling applications.
Request a Quote
There are no products to list in this category.